Midiana (Drospirenone, Ethinylestradiol | Lactose Anhydrous)

• Midiana, a combined oral contraceptive, is indicated for hormonal contraception and menstrual cycle regulation.
• Contraception: provides reliable prevention of pregnancy in women of reproductive age.
• Menstrual cycle regulation: helps achieve more predictable and lighter menstrual bleeding.
• Management of hormone‑related menstrual disorders: reduces dysmenorrhea and improves cycle regularity.

• Drospirenone/Ethinylestradiol works by suppressing the hypothalamic‑pituitary‑ovarian axis, inhibiting the release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH) to prevent ovulation. Drospirenone acts as a progestogen with anti‑mineralocorticoid activity, while ethinylestradiol provides estrogenic support. The combination also thickens cervical mucus and induces endometrial changes that hinder implantation, delivering effective hormonal contraception.

Midiana may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: swelling or discomfort.
• Spotting or breakthrough bleeding: irregular light bleeding.
• Weight gain: modest increase in body weight.
• Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects

• Deep vein thrombosis: blood clot formation in veins.
• Pulmonary embolism: clot migration to lung vessels.
• Stroke: cerebrovascular accident due to clot or hemorrhage.
• Myocardial infarction: heart attack from coronary blockage.
• Severe allergic reaction: anaphylaxis, rash, or swelling.
• Liver disorders: jaundice, hepatitis, or abnormal liver enzymes.

• Before prescribing Midiana, clinicians should evaluate individual risk factors and contraindications.
• Pregnancy contraindication: do not use in women who are or may become pregnant.
• Smoking restriction: avoid in women over 35 who smoke.
• Thromboembolic history: contraindicated in patients with prior clotting events.
• Hypertension: monitor blood pressure and avoid if uncontrolled.
• Liver disease: use with caution in hepatic impairment.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Midiana can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Rifampin: strong CYP3A4 inducer that reduces contraceptive efficacy.
• St. John’s wort: herbal inducer that may diminish hormone levels.
• Certain anticonvulsants (e.g., carbamazepine, phenytoin): decrease plasma concentrations.

Moderate Interactions (Monitor Closely)

• Antifungal agents (e.g., ketoconazole, itraconazole): may increase hormone exposure.
• SSRIs (e.g., fluoxetine, sertraline): potential for modest pharmacokinetic changes.
• Antihypertensives (e.g., ACE inhibitors): monitor blood pressure control.
• Antidiabetic drugs: watch for altered glucose control.
• Herbal supplements (e.g., ginseng): possible interaction with metabolism.